Ipratropium Bromide Spray as Treatment for Sialorrhea in Children

Overview

Double-blind, clinical trial investigating the effects of ipratropium spray versus placebo spray in children with sialorrhea

Full Title of Study: “Ipratropium Bromide Spray as Treatment for Sialorrhea in Children: a Randomized, Double-blind, Placebo-controlled Crossover Study”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Crossover Assignment
    • Primary Purpose: Treatment
    • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: October 1, 2019

Detailed Description

Excess drooling, or sialorrhea, is a chronic problem seen in pediatric patients with oral-motor dysfunction or neurodevelopmental abnormalities. Despite significant social and physical detriment from sialorrhea, an effective and safe treatment remains elusive.

The investigator's objective is to study the effect of sublingual ipratropium (an anticholinergic aerosol spray) on sialorrhea in the pediatric population

Method: A double-blind, randomized, placebo-controlled cross-over trial of sublingual ipratropium bromide application in pediatric patients with inappropriate drooling. Patients are recruited from the sialorrhea clinic and informed consent is obtained. Patients are randomized to receive ipratropium bromide, 1- 2 metered doses (sprays) of active drug (21 micrograms per metered dose) or matching placebo, every 6 hours up to a maximum of 4 times per day, in a double-blind, cross-over design using randomization tables. Total treatment length is two weeks for each limb of the study with a 2 week washout period. The primary outcome measure is the reporting of sialorrhea using a validated scales. Secondary outcome includes global assessment of treatment, patient satisfaction, and adverse effects.

Interventions

  • Drug: Ipratropium bromide
    • ipratropium bromide via metered dose spray (21 micrograms per spray)
  • Other: Placebo
    • normal saline delivered via metered dose spray

Arms, Groups and Cohorts

  • Experimental: Intervention
    • ipratropium bromide administered via metered dose spray (21 micrograms per spray). 1-2 spray sublingual or to buccal mucosa every 6 hours up to 4 times a day
  • Placebo Comparator: Placebo
    • normal saline administered via metered dose spray. 1-2 spray sublingual or to buccal mucosa every 6 hours up to 4 times a day

Clinical Trial Outcome Measures

Primary Measures

  • Change in Drooling Severity and Frequency Scale
    • Time Frame: Change from baseline sialorrhea at 2 weeks following each treatment arm
    • Also referred to as the Thomas Stonell and Greenberg scale. This is a validated tool using patient reported scores for drooling severity and frequency. Drooling severity is scored on a scale with minimum value of 1 and maximum value of 5. A higher value represents a worse outcome. The frequency is scored on a scale with minimum value of 1 and maximum value of 4. A higher value represents a worse outcome. The subscales (severity and frequency) can be interpreted independently or combined through addition to compute a total score.
  • Change in Drooling impact scale
    • Time Frame: Change from baseline sialorrhea at 2 weeks following each treatment arm
    • The drooling impact scale is a validated self-administered questionnaire used to measure saliva-control in children. The scale consists of 10 questions/subscales, each with a minimum score of 1 and a maximum score of 10. For all subscales, the higher value represents a worse outcome. The total score is reported and is calculated by adding the score of all 10 subscales.

Secondary Measures

  • Patient Global Impression of Improvement Scale
    • Time Frame: At start of trial and weekly self recording up to 8 weeks
    • The Patient Global Impression of improvement scale is a single 7-point scale that requires the patient/caregiver to assess how much the illness has improved or worsened relative to a baseline state at the beginning of the intervention. The minimum score is 1 and the maximum score is 7. A higher value represents a worse outcome. To be collected through patient booklet
  • Adverse effect
    • Time Frame: Intermittent up to 8 weeks
    • Documentation of all adverse effects encountered during study period
  • Patient feedback
    • Time Frame: Weekly self recording up to 8 weeks.
    • Open ended patient comment related to the intervention. To be collected through patient booklet

Participating in This Clinical Trial

Inclusion Criteria

  • Children and adolescents aged 5-18 with a history of excessive drooling

Exclusion Criteria

  • known hypersensitivity to ipratropium bromide
  • surgery for sialorrhea within one year
  • the concurrent use of acetylcholinesterase inhibitors, cholinergic agents, or anticholinergic agents
  • botulinum toxin for drooling within the preceding six months
  • a history of glaucoma
  • the presence of clinically significant urinary retention or outflow obstruction as evidenced by patient history or documented urodynamic studies

Gender Eligibility: All

Minimum Age: 5 Years

Maximum Age: 18 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • London Health Sciences Centre
  • Provider of Information About this Clinical Study
    • Principal Investigator: Peng You, Principle Investigator, Department of Otolaryngology Head and Neck Surgery, Western University – London Health Sciences Centre
  • Overall Official(s)
    • Julie Strychowsky, MD, Principal Investigator, London Health Science Centre
  • Overall Contact(s)
    • Julie Strychowsky, MD, 519 685 8500, julie.strychowsky@lhsc.on.ca

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.